Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 10,24€(+150,98%). Der Median liegt bei 10,24€(+150,98%).
Kaufen | 7 |
Halten | 1 |
Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option
FLORHAM PARK, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the “Company”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the closing of its previously announced underwritten public offering for gross proceeds of approximately $6.9 million prior to deducting underwriting commissions and offering expenses. The offering includes participation from healthcare dedicated funds and executive management.» Mehr auf globenewswire.com
Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering
FLORHAM PARK, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the “Company”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the pricing of an underwritten public offering for gross proceeds of approximately $6 million prior to deducting underwriting commissions and offering expenses.» Mehr auf globenewswire.com
Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement
Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for Triple-Negative Breast Cancer FLORHAM PARK, N.J. and WEST VALLEY CITY, Utah, June 26, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, and Nusano, a physics company transforming the production of radioisotopes, today announced the signing of a multi-year supply agreement in which Nusano will provide Cellectar with iodine-125 (I-125) and actinium-225 (Ac-225) for its clinical studies and future commercial needs.» Mehr auf globenewswire.com
Unternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 0,00 | - |
Bruttoeinkommen | 0,00 | 100,00% |
Nettoeinkommen | −6,10 Mio | 69,47% |
EBITDA | −5,92 Mio | 46,40% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 188,73 Mio€ |
Anzahl Aktien | 46,08 Mio |
52 Wochen-Hoch/Tief | 80,63€ - 3,72€ |
Dividenden | Nein |
Beta | 0,52 |
KGV (PE Ratio) | −9,01 |
KGWV (PEG Ratio) | −0,18 |
KBV (PB Ratio) | 26,80 |
KUV (PS Ratio) | 0,00 |
Unternehmensprofil
Name | Cellectar Biosciences |
CEO | James V. Caruso |
Sitz | Florham Park, nj USA |
Website | |
Industrie | Chemikalien |
Mitarbeiter | 11 |
Assets entdecken
Shareholder von Cellectar Biosciences investieren auch in folgende Assets